Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Neoplasms: early-phase trial registry
12 of 32 indexed Pancreatic Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #477 of 28,707 conditions by registered trial count.
32 US clinical trials · 12 currently recruiting · #477 of 28,707 conditions by registered trial count
Pancreatic Neoplasms: 32 US clinical trials tracked, 12 recruiting.
Pancreatic Neoplasms is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Nuvance Health, running 3 of these trials.
Enrollment posture brief
Registry condition pancreatic-neoplasms
OPEN 12 | RECR 38% | LATE 2 | EARLY 13 | RANK #477 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Pancreatic Neoplasms lists 12 open slots (38% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Neoplasms is recruiting below its size-band peers.
12 of 32 indexed trials (37.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Neoplasms trials is spread across many organizations.
Nuvance Health accounts for 3 of 32 trials (9.4%). 24 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Neoplasms enrolment sits around 65 participants.
Median target enrolment is 65 among the 31 trials that report a genuine target (sentinel values excluded). 16 of those (51.6%) plan for fewer than 100 participants.
-
Pancreatic Neoplasms splits between interventional and observational designs.
18 interventional and 14 observational studies make up this index (56.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
32 total, page 1 of 1
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
Johns Hopkins University
NCT04473794
UCSF PANC Cyst Registry
University of California, San Francisco
NCT04291651
Pancreatic Cancer Detection Consortium
City of Hope Medical Center
NCT06388967
Determining Individualized Cancer Therapy in Pancreatic Cancer
Medical College of Wisconsin
NCT05914987
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
NCT01950572
ExoLuminate Study for Early Detection of Pancreatic Cancer
Biological Dynamics
NCT05625529
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
Nuvance Health
NCT03937453
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Nuvance Health
NCT04406831
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
Nuvance Health
NCT03250078
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03977233
Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)
AdventHealth
NCT02531607
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT05736731
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05571839
Hepatic Resection for Metastatic Pancreatic Cancer
Duke University
NCT02892305
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT04137536
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Celgene
NCT01964430
Chromogranin A as Blood Marker in Cancer Patients
Brahms
NCT03817866
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
NCT02311361
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
University of Wisconsin, Madison
NCT00634751
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Threshold Pharmaceuticals
NCT00102752
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Mauna Kea Technologies
NCT01770405
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Ohio State University Comprehensive Cancer Center
NCT00201838
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Indiana University
NCT02780648
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
AdventHealth
NCT03152487
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
St. Luke's-Roosevelt Hospital Center
NCT00220649
Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms
Case Comprehensive Cancer Center
NCT05225038
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
NCT01161186
Feasibility of Using Ultrasound to Track Respiration Motion
Medical College of Wisconsin
NCT02173353
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Andrew Ko
NCT01383538
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Eli Lilly and Company
NCT00035035
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Neoplasms page
32 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Pancreatic Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nuvance Health sponsors the most Pancreatic Neoplasms trials on record, review their full trial history before evaluating a specific study. See Nuvance Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Neoplasms condition card totals 32 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.